References
- Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al. Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686–93.
- Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–17.
- Taniguchi M, Tsurikisawa N, Higashi N, Saito H, Mita H, Mori A et al. Treatment for Churg–Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int. 2007;56: 97–103
- Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. J N Eng Med. 2010;363: 211–220
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Eng J Med. 2010;363: 221–232
- Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg–Strauss syndrome. Ann Rheum Dis. 2006;65: 1116–1117
- Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg–Strauss syndrome. Ann Rheum Dis. 2006;65: 557–559
- Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47: 1104–1105
- Saech J, Owczarczyk K, Rosgen S, Petereit H, Hallek M, Rubbert-Roth A. Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis. 2010;69: 1254–1255
- Donvik KK, Omdal R. Churg–Strauss syndrome successfully treated with rituximab. Rheumatol Int. 2011;31: 89–91
- Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg–Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26: 2865–2871
- Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107: 387–393
- Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol. 2012;39: 1019–1025
- Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis. 2004;63: 1649–1654
- Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg–Strauss syndrome. Clin Exp Rheumatol. 2012;30: S62–S65.
- Guilpain P, Auclair JF, Tamby MC, Servettaz A, Mahr A, Weill B et al. Serum eosinophil cationic protein: a marker of disease activity in Churg–Strauss syndrome. Ann N Y Acad Sci. 2007;1107: 392–399
- Hurst S, Chizzolini C, Dayer JM, Olivieri J, Roux-Lombard P. Usefulness of serum eosinophil cationic protein (ECP) in predicting relapse of Churg and Strauss vasculitis. Clin Exp Rheumatol. 2000;18: 784–785.